NO932148L - Fusjonspolypeptider - Google Patents

Fusjonspolypeptider

Info

Publication number
NO932148L
NO932148L NO93932148A NO932148A NO932148L NO 932148 L NO932148 L NO 932148L NO 93932148 A NO93932148 A NO 93932148A NO 932148 A NO932148 A NO 932148A NO 932148 L NO932148 L NO 932148L
Authority
NO
Norway
Prior art keywords
dpp
fusion polypeptides
fusion protein
extension
proteins
Prior art date
Application number
NO93932148A
Other languages
English (en)
Other versions
NO932148D0 (no
Inventor
Teresa M Kubiak
Satish K Sharma
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO932148D0 publication Critical patent/NO932148D0/no
Publication of NO932148L publication Critical patent/NO932148L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Et ikke-naturlig forekommende fusjonsprotein omfattende en forlengelsespeptiddel kovalent kjedet ved dens C-ende til N-enden av en biologisk aktiv del, er beskrevet. Forlengelses- peptiddelen kan fjernes ved DPP IV- spaltning. Anvendelse av fusjonspro- teiner med DPP IV-spaltbare forlengel- sespeptiddeler i medisinske preparater er beskrevet. En metode for rensing av ønskede proteiner fra en blanding inneholdende et fusjonsprotein, er be- skrevet.
NO93932148A 1990-12-13 1993-06-11 Fusjonspolypeptider NO932148L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62672790A 1990-12-13 1990-12-13
PCT/US1991/009152 WO1992010576A1 (en) 1990-12-13 1991-12-12 Fusion polypeptides

Publications (2)

Publication Number Publication Date
NO932148D0 NO932148D0 (no) 1993-06-11
NO932148L true NO932148L (no) 1993-08-09

Family

ID=24511577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93932148A NO932148L (no) 1990-12-13 1993-06-11 Fusjonspolypeptider

Country Status (13)

Country Link
EP (1) EP0561971A1 (no)
JP (1) JPH06503473A (no)
AU (1) AU662508B2 (no)
CA (1) CA2094512A1 (no)
CZ (1) CZ109393A3 (no)
FI (1) FI932680A0 (no)
HU (1) HUT69963A (no)
IE (1) IE914347A1 (no)
NO (1) NO932148L (no)
RU (1) RU2114119C1 (no)
SK (1) SK60893A3 (no)
TW (1) TW213923B (no)
WO (1) WO1992010576A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9906715D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
BR0001606A (pt) * 1999-04-12 2001-04-24 Pfizer Prod Inc Composições de hormÈnio de crescimento e de hormÈnio de liberação de hormÈnio de crescimento
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
JP2003514532A (ja) * 1999-11-19 2003-04-22 トランスカーヨティック セラピーズ インコーポレイテッド 生成物の産生量を最適化するための核酸構築体
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
EP1205551A1 (en) * 2000-11-09 2002-05-15 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DK2402754T4 (da) † 2006-03-06 2023-08-28 Amunix Operating Inc Ustrukturerede rekombinante polymerer og anvendelser deraf
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
CN102947324A (zh) * 2010-01-29 2013-02-27 阿切尔丹尼尔斯密德兰公司 结合有工业意义的小分子的肽结构域
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CN111051338B (zh) * 2017-06-29 2024-12-03 乌雷卡有限公司 具有改进的药物学性能的前药肽
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
ATE113965T1 (de) * 1989-06-16 1994-11-15 Upjohn Co Stabilisierte, starke grf-analoga.
EP0527778B1 (en) * 1990-04-09 1996-06-19 The Upjohn Company Improved process of purifying recombinant proteins and compounds useful in such process

Also Published As

Publication number Publication date
WO1992010576A1 (en) 1992-06-25
RU2114119C1 (ru) 1998-06-27
IE914347A1 (en) 1992-06-17
EP0561971A1 (en) 1993-09-29
HU9301705D0 (en) 1993-10-28
FI932680L (fi) 1993-06-11
CZ109393A3 (en) 1994-01-19
HUT69963A (en) 1995-09-28
JPH06503473A (ja) 1994-04-21
SK60893A3 (en) 1993-10-06
FI932680A7 (fi) 1993-06-11
CA2094512A1 (en) 1992-06-14
NO932148D0 (no) 1993-06-11
AU662508B2 (en) 1995-09-07
FI932680A0 (fi) 1993-06-11
AU9116591A (en) 1992-07-08
TW213923B (no) 1993-10-01

Similar Documents

Publication Publication Date Title
Matsuo et al. Synthesis of the porcine LH-and FSH-releasing hormone by the solid-phase method
Gregory et al. The primary structure of human urogastrone
EP0105014B1 (en) Repair of tissue in animals
RU93045577A (ru) Слитные полипептиды
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
NO178789B (no) Fremgangsmåte for fremstilling av gamma-interferonpolypeptid med forbedret stabilitet, ekspresjonsvektor samt DNA-sekvens kodende for polypeptidene
NZ504752A (en) Hydrophobically-modified protein compositions (particularly hedgehog proteins)
GR3026436T3 (en) Stabilization of somatotropins by modification of cysteine residues
Van Leen et al. Production of human interleukin-3 using industrial microorganisms
JPS6410999A (en) Production of physiologically active peptide containing cysteine residue
DK149092C (da) Analogifremgangsmaade til fremstilling af tripeptider eller farmaceutisk acceptable syreadditionssalte deraf
Schwartz et al. A highly potent insulin: des-(B26-B30)-[AspB10, TyrB25-NH2] insulin (human).
Meloun et al. Amino acid sequence of bovine spleen cathepsin B.
Heath et al. (ACB) human proinsulin, a novel insulin agonist and intermediate in the synthesis of biosynthetic human insulin.
Burke et al. Superactive insulins
WO1994018233A1 (en) Thymosin alpha-1 derivatives
Créminon et al. Synthetic peptide substrates as models to study a pro-ocytocin/neurophysin converting enzyme
FR2408580A1 (fr) Compositions de polypeptides contenant la sequence l-arginine-l-lysine-(acide l-aspartique)-l-valine-l-tyrosine, leur procede d'obtention et compositions therapeutiques en comportant
KR890014735A (ko) 변형 단백질
YU64192A (sh) Analozi insulina
AU6393990A (en) Hiv related peptides
YAMASHIRO et al. β‐Endorphin: Synthesis and radioreceptor‐binding activity of the ostrich hormone
Massey et al. Guinea pig proinsulin. Primary structure of the C-peptide isolated from pancreas
YAMASHIRO et al. β‐Endorphin: Synthesis and properties of double‐headed and related analogs
US4330465A (en) Novel β-endorphin analogs